Emerging technologies had marked the emergence of the Industry 4.0 era. Despite the problems experienced with COVID-19, many experts believe that Industry 4.0 is an inevitable reality that many businesses must face in the future. One of those technologies is the Internet of Things (IoT), which may generate so-called "big data" that will be useful for business insight. However, after performing a rigorous literature review, articles related to the impact of the IoT and big data implementations for business performance in the form of a model were rarely found. Among the available literature, some elements that may be considered are: (1) business process improvement;(2) marketing strategies; (3) business management innovation; and (4) business performance. Therefore, this paper proposes an implementation model of IoT and big data to pursue business performance. Thus, a survey was conducted with managerial respondents from the manufacturing industry. For analysis purposes, a partial least squares structural equation modeling (PLS-SEM) methodology was implemented to examine the fitness of the model. The analysis was conducted in Smart PLS 3.0, and the goodness of fit (GoF) calculated for this model was 0.63, larger than the required 0.38 for a robust and accurate result. This model was implemented in a sample manufacturing company to seek improvement. Regarding this effort, several improvements were added as input by the manufacturing players to enhance the model.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish the feasibility of personal dendritic cell vaccines to the SARS-CoV-2 spike protein, establish the safety of a single subcutaneous vaccine injection, and determine the antigen-specific immune response following vaccination. In Phase 1, 31 subjects were assigned to one of nine formulations of autologous dendritic cells and lymphocytes (DCL) incubated with 0.10, 0.33, or 1.0 µg of recombinant SARS-CoV-2 spike protein, and admixed with saline or 250 or 500 µg of granulocyte-macrophage colony-stimulating factor (GM-CSF) prior to injection, then assessed for safety and humoral response. In Phase 2, 145 subjects were randomized to one of three formulations defined by incubation with the same three quantities of spike protein without GM-CSF, then assessed for safety and cellular response. Vaccines were successfully manufactured for every subject at point-of-care. Approximately 46.4% of subjects had a grade 1 adverse event (AE); 6.5% had a grade 2 AE. Among 169 evaluable subjects, there were no acute allergic, grade 3 or 4, or serious AE. In Phase 1, anti-receptor binding domain antibodies were increased in 70% of subjects on day-28. In Phase 2, in the 127 subjects who did not have high levels of gamma interferon-producing cells at baseline, 94.4% had increased by day 14 and 96.8% by day 28. Point-of-care personal vaccine manufacturing was feasible. Further development of such subject-specific vaccines is warranted.
The goal of the research was to evaluate the effectiveness of Kirkpatrick model and Return on Investment of Training at PT XYZ. Observation was applied to this research. The result has shown several facts such as trainee’s feedback score was 4,62 above 4,10 as required by the company in terms of reaction, the average final exam score was 3,66 above 3,00 as required by the company in terms of learning, the trainees’ superiors’ feedback score was 3,53 above 3,00 as required by the company and Return on Investment of Training (ROI-Training) was 58,88% above 15% as required by the company. With these results, the company can conclude that the program is effective in nurturing its supervisory leaders.
Patients with chronic kidney disease (CKD), including dialysis and transplant patients, are at greater risk of contracting SARS-CoV-2 due to kidney dysfunction and preexisting comorbidities. To date, a specific guideline on managing these high-risk patients infected with COVID-19 has not been established. As the current management of COVID-19 comprises mainly experimental drugs, the authors aim to provide information on dosing adjustments at different stages of kidney dysfunction and notable renal side effects. We performed a nonsystematical review of currently available COVID-19 drugs exploring several different clinical trial databases and search browsers. Several antivirals and monoclonal antibodies used in COVID-19 treatment require dosage adjustments in kidney dysfunction. In a global pandemic setting, nephrologists need to consider the appropriate dosage according to the renal function and closely monitor the side effects of different drug combinations to obtain the optimum therapeutic effect while avoiding further renal damage. Further studies are required to determine the safety and efficacy of these drugs in renal patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.